SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VISX
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bajasurfer who wrote (775)1/10/1999 4:48:00 PM
From: Jim Mac  Read Replies (2) of 1754
 
I also see $200-300 in 1999 (pre-split), barring any problems or unusually high expenses, like legal, marketing, or Japan costs.

The analysts are assuming the procedure fee to Visx will drop to $200, and S2 sales will shrink due to ATCI, Nidek, maybe LASE and BOL.

Without hyperopia, ATCI will not be as competitive, and without astigmatism AND hyperopia, Nidek is dead in the water, even if they can sell in U.S. in 1999.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News